Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Cell Therapies

Section: Biopharma Insights     View all sections


[Interview] Advancing Off-the-shelf Cellular Medicines to Fight COVID-19

   by Andrii Buvailo    1208
[Interview] Advancing Off-the-shelf Cellular Medicines to Fight COVID-19

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in developing allogeneic (off-the-shelf) cellular medicines, just announced that the first COVID-19 infected patients have been dosed with remestemcel-L, the company’s proprietary allogeneic cellular medicine. This study is conducted within the framework of the 300-patient randomized placebo-controlled Phase 3 trial underway in North America which focuses on patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support.